Shukra Pharmaceuticals Q4 Net Loss of ₹1.73 Crore

Board approved audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026, reporting a net loss of ₹1.73 crore for the quarter.
Recommended a final dividend of ₹0.01 per equity share (1%) for FY 2025-26, subject to shareholder approval at the AGM.
Allotted 17.35 lakh equity shares to promoters upon full conversion of warrants, increasing paid-up capital to ₹43.96 crore.
Auditors issued unmodified opinions on both standalone and consolidated financial results, confirming compliance with SEBI LODR regulations.